Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nefazodone Hydrochloride

FDA-approved product (tablet, oral), marketed as Nefazodone Hydrochloride, Serzone.

Registered studies
6
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nefazodone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nefazodone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nefazodone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

    NCT02977299 · start 2017-07-13

    Registered record
    Registry ID
    NCT02977299
    Conditions
    Treatment Resistant Major Depressive Disorder
    Interventions
    Aripiprazole; Repetitive transcranial magnetic stimulation (rTMS); Venlafaxine XR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-07-13
    Completion
    2022-04-24
    Enrolment
    278

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Resistant Major Depressive Disorder
    InterventionAripiprazole; Repetitive transcranial magnetic stimulation (rTMS); Venlafaxine XR
    PhasePhase 4
    Registry statusCompleted

  • Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals

    NCT00249509 · start 2000-09

    Registered record
    Registry ID
    NCT00249509
    Conditions
    Marijuana Abuse
    Interventions
    Nefazodone; Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-09
    Completion
    2004-09
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarijuana Abuse
    InterventionNefazodone; Bupropion
    PhasePhase 2
    Registry statusCompleted

  • Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10

    NCT00000293 · start 1999-01

    Registered record
    Registry ID
    NCT00000293
    Conditions
    Cocaine-Related Disorders
    Interventions
    Nefazodone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-01
    Completion
    2001-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders
    InterventionNefazodone
    PhasePhase 3
    Registry statusCompleted

  • Nefazodone in the Treatment of Cocaine Dependence and Depression - 4

    NCT00015210 · start 1997-02

    Registered record
    Registry ID
    NCT00015210
    Conditions
    Cocaine-Related Disorders; Substance-Related Disorders
    Interventions
    Nefazodone; Psychosocial Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-02
    Completion
    Not recorded
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders; Substance-Related Disorders
    InterventionNefazodone; Psychosocial Treatment
    PhasePhase 2
    Registry statusCompleted

  • Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3

    NCT00000286 · start 1996-12

    Registered record
    Registry ID
    NCT00000286
    Conditions
    Cocaine-Related Disorders
    Interventions
    Nefazodone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1996-12
    Completion
    2001-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-Related Disorders
    InterventionNefazodone
    PhasePhase 2
    Registry statusCompleted

  • Nefazodone in the Treatment of Social Phobia

    NCT00231348

    Registered record
    Registry ID
    NCT00231348
    Conditions
    Social Anxiety Disorder (SAD)
    Interventions
    Nefazodone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSocial Anxiety Disorder (SAD)
    InterventionNefazodone
    PhasePhase 4
    Registry statusCompleted